Click to open
Skip to content
HepHIV
HepHIV Conference
  • Home login
  • Programme
  • Speakers Corner
  • Privacy Policy
  • Eposters
  • Lobby
  • Home login
  • Programme
  • Speakers Corner
  • Privacy Policy
  • Eposters
  • Lobby

Programme
Download the programme in pdf
Download the Eposters in pdf

HepHIV 5 - 7 May 2021 (Time CEST) / Lisbon & Virtual

Filter by session
Opening Session
Side Meetings
Plenary Session
Abstract driven session
E-Poster session
EU Health Project Symposium
Closing Session
Break
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
Wednesday, 5 May 2021
Wednesday, 5 May 2021
EATG stakeholder meeting regarding diagnostics
09:30 - 11:00
Side meetings

EATG Stakeholders Meeting Regarding Diagnostics HepHIV 2021 conference side-meeting

Time: 5 May 2021, 9:30-11:00 CEST
Participants: Diagnostics companies, EuroTEST, ECDC, WHO, community and civil society organizations providing screening services.

Meeting background

The WHO and ECDC have recommended that early detection and treatment of HIV and viral hepatitis among key populations in Europe could be enhanced by implementing self-testing/sampling options and permissions for lay providers to administer tests in community settings. The burden of COVID-19 on health systems has further challenged key population access to HIV, TB, viral hepatitis, and STI testing services and counselling. In response to the pandemic, there is evidence of individual community-based organisations (CBO) initiating diversified testing service delivery options such as self-testing/sampling. While impressive, such interventions are siloed, unfeasible, and unsustainable for many regions.

There is a need for diagnostics developers/manufacturers and community-level organizations to collaboratively initiate sustainable testing interventions and adapt strategic approaches to reach the undiagnosed within key populations.

In continued collaboration with EuroTEST, the EATG will host an initial multi-level stakeholder meeting regarding HIV, TB, viral hepatitis and other STIs diagnostics at HepHIV 2021.

Meeting Objectives

i. Provide a community-level perspective on self-testing/sampling diagnostic tools and testing service delivery ii. Examine diagnostic companies’ plans/commitment to community; specifically, in regards to cost of diagnostics and regulatory/legal barriers
iii. Provide a platform for dialogue between CBOs and Diagnostic developers, and potentially identify collaborative opportunities.

Expected outcomes

Findings from this meeting will be summarized and shared to the main HepHIV 2021 conference attendees. This meeting will contribute to bilateral dialogue on the use of testing technologies to support key population empowerment, early detection, linkage to care, and facilitate HIV management. Dialogue between industry and community will open opportunities for product co-design and implementation, and establish new partnerships.

Agenda

9:30-9:40 9:40-9:55

Welcome and meeting objectives, Magdalena Ankiersztejn-Bartczak, CEO Foundation for Social Education
Community organisations perspectives: experiences with self-test diagnostics
Christos Krasidis, Cyprus Checkpoint

Mihai Lixandru, ARAS - Asociatia Romana Anti-SIDA Robert Hejzak, Czech AIDS Assistance

9:55-10:15

Diagnostics companies plans and commitment to community level

Orasure
Owen Mumford

10:30-10:50
Moderated discussion of opportunities to collaborate

10:50-11:00
Follow-up points & meeting wrap-up, Magdalena Ankiersztejn-Bartczak, CEO Foundation for Social Education



Lisbon Fast Track City: HCV testing and treatment in the community – learning from harm reduction and people who use drugs
11:30 - 13:00
Side meetings

Lisbon Fast Track City: HCV testing and treatment in the community – learning from harm reduction and people who use drugs

HepHIV 2021 conference side-meeting 

Time/date: 5 May 2021, 11:30-13:00 CEST

Participants: Open to all conference participants – no pre-registration needed

Meeting background and objectives

During this session, the experience and results of five different HCV treatment outreach interventions in three Fast-Track Cities – Lisbon, Oporto and Paris – will be presented and discussed. The audience will be invited to actively engage in collectively reflecting on the importance of building on learnings from harm reduction and involving peers and how HCV treatment outreach interventions can be further leveraged to achieve elimination of Hepatitis C by 2030.

Agenda

      • 5’ initial intervention by each participant

      • Discussion (open to the audience participation)

Participants:

      • Hugo Faria Ares do Pinhal/Mobile Outreach Team

      • Luís Mendão GAT- IN-Mouraria/ Harm Reduction Centre

      • Inês Marinho Crescer/ Outreach Team

      • Sérgio Rodrigues APDES- GIRUGaia/Mobile Outreach Team

      • Elisabeth Avril GAIA Paris/Drug Consumption Room

Moderators:

      • Alexis Goosdeel – European Monitoring Centre for Drugs and Drug Addiction

      • Ricardo Fuertes – Câmara Municipal de Lisboa / Lisbon Fast Track City

Fast-Track Cities: Actioning HCV Elimination in European Urban Settings
13:30 - 14:30
Side meetings

Fast-Track Cities: Actioning HCV Elimination in European Urban Settings

 

HepHIV 2021 Conference Side-Meeting

 

 

Time/Date: 13:30-14:30 CEST, 5 May 2021

 

Participants: Open to all conference participants – no pre-registration needed

 

Meeting Background

 

The Paris Declaration on Fast-Track Cities calls upon cities and municipalities around the world to accelerate local actions towards ending their HIV, TB, and viral hepatitis epidemics by 2030. COVID-19 has placed a significant strain on national and subnational health systems at a critical moment in the context of HCV elimination. According to mathematical modelling, the 1-year delay in advancing HCV programmatic targets may have resulted in 44,800 excess hepatocellular carcinoma cases and 72,300 excess liver-related deaths, relative to a no-delay scenario globally, from 2020 to 2030, with the most excess hepatocellular carcinoma and liver-related deaths among high-income countries.1 However, clinician and community leaders across the European Fast-Track Cities network worked diligently and strategically over the past year to maintain a continuity of HCV services with the aim of mitigating disruptions across the HCV care continuum.

 

Meeting Objectives

 

The meeting will help define a strategy for actioning HCV elimination in European urban settings in alignment with World Health Organization (WHO) and United Nations (UN) goals and targets. Moreover, the meeting will showcase urban HCV efforts in two European Fast-Track Cities that have leveraged their existing HIV responses to advance HCV elimination goals despite the challenges posed by their cities’ COVID-19 epidemics.

 

Agenda

 

Time

Presentation

Presenter

 

Moderator: Dr José M. Zuniga, President/CEO, IAPAC and Fast-Track Cities Institute

13:30h

Welcome, Context, and Introductions (5 minutes)

Dr José M. Zuniga

President/CEO

IAPAC and

Fast-Track Cities Institute

13:35h

Leveraging Fast-Track Cities to End Urban HCV Epidemics: An Urban Agenda to Find and Cure the Missing Millions (10 minutes)

Mr Cary James

President

World Hepatitis Alliance

Case Studies

13:45h

HIV and HCV Screening in the Midst of the COVID-19 Pandemic: Seizing an Opportunity across Homeless Shelters in London (10 minutes)

Prof. Jane Anderson

Co-Chair

Fast-Track London

13:55h

Urban HCV Micro-Elimination in Action: Examining the AEHVE Hep C Free Experience in Sevilla and Valencia as a Model for Europe (10 minutes, pre-recorded presentation)

Dr. Javier García-Samaniego

Coordinator

AEHVE Hep C Free

14:05h

Q&A and Open Discussion (20 minutes)

Faculty and Participants

14:25h

Review of Key Take-Away Messages (5 minutes)

Dr José M. Zuniga

President/CEO

IAPAC and

Fast-Track Cities Institute

 

Reference

 

        1. Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31-36.

OPENING SESSION
15:00 - 17:00
OPENING SESSION

Time (CEST)

Presentation No.

Session

Moderators and speakers

15:00-17:00

OS

OPENING SESSION

Session objectives: To provide an overview of the conference objectives, scope and expected outcomes of the conference. Set the scene through policy, technical and community perspectives on European progress toward the Sustainable Development Goals and other global targets, including challenges ahead and priorities for maintaining HIV, viral hepatitis, STIs and TB on the political agenda.

Moderators:

Daniel Simões, HepHIV2021 Conference Co-chair, Coalition Plus/GAT, Portugal

Jürgen Rockstroh, HepHIV2021 Conference Co-chair, HIV Outpatient Clinic, University of Bonn, Germany

15:00-15:10

OS/00

Welcome to the HepHIV 2021 Lisbon & Virtual Conference

Ricardo Baptista Leite, Local conference co-chair,
MP Portugal, UNITE

15:10-15:20

OS/01

Conference objectives and overview

Dorthe Raben, EuroTEST Initiative, CHIP, University of Copenhagen

15:20-15:30

OS/02

Welcome message from the Portuguese Minister of Health

António Lacerda Sales, Assistant State Secretary for Health, Portugal

15:30-15:40

OS/03

Welcome from the European Commission: The EU response on HIV, viral hepatitis, STIs and TB in the future

John Ryan, Director of Public Health, DG Sante, European Commission

15:40-15:50

OS/04

Post-2020/COVID-19 and progress towards the SDG targets: Where are we?

Andrea Ammon, Director, European Centre for Disease Prevention and Control (ECDC)

15:50-16:00

OS/05

‘The changed landscape’ – providing testing for HIV/STIs/hepatitis/TB in the era of COVID-19

Hans Kluge, Regional Director, WHO Regional Office for Europe. Represented by Nicole Seguy, WHO Regional Office for Europe in the live discussion

16:00-16:10

OS/O6

Country Spotlight: Portugal’s progress in reaching the global targets and interventions for integration of testing

Rui Portugal, Deputy Director-General of Health, National Directorate of the Portuguese Ministry

16:10-16:20

OS/07

Community perspective on enabling environments for integrated testing and linkage to care across Europe

Daniel Simões, Coalition Plus/GAT, Portugal

16:20-17:00

 

Panel discussion

 

Thursday, 6 May 2021
Thursday, 6 May 2021
COBATEST network executive meeting (Closed meeting))
10:00 - 13:00
Side meetings

COBATEST network executive meeting (Closed meeting)

PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: COVID-19’s impact on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building stronger systems and communities in light of lessons learned
13:00 - 14:15
Plenary Session

Time (CET)

 

Session

Moderators and speakers

13:00-14:15

PS1

PLENARY SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better

Session objectives: To share the latest evidence of how the COVID-19 pandemic has impacted prevention, testing and linkage to care for HIV, viral hepatitis and STIs; share successful models of service adaptation and discuss how to build stronger systems and communities in light of lessons learned.

Moderators:

Nicole Seguy, WHO Regional office for Europe

Jeffrey Lazarus, Barcelona Institute for Global Health (IS Global)

13:00-13:10

PS1/01

Keynote address:Perspectives from the US National Institute of Allergy and Infectious Diseases of the National Institutes of Health

H.Clifford Lane, Deputy Director for Clinical Research and Special Projects , National Institute of Allergy and Infectious Diseases (NIAID), USA

13:10-13:20

PS1/02

Impact of the COVID-19 pandemic on testing and linkage to care for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region

A.R. Stengaard1, A. Sullivan2, J.D Kowalska3, C. Rokx4, D. Raben1, D. Simões5, The EuroTEST COVID-19 impact assessment consortium of partners

13:20-13:30

PS1/03

s.a.m. Health: Germany’s first digital sexual health service is providing COVID-safe remote STI testing and counselling during the Covid-19 Pandemic and beyond

A. Schafberger1, K.M. Dymek2, G. Waltinger3, G. Davies4, C. Kantwerk1

13:30-13:40

PS1/04

Rapid HIV testing and linkage in rehabilitation centers during COVID-19 pandemics, Yekaterinburg and Sverdlovsk region, Russia

V. Evseeva1, M. Greysman1, V. Stanilevskiy2, N. Mironova2, A. Chuykov3, A.M. Żakowicz3

13:40-13:50

PS1/05

European testing week: adaptation of testing services during the COVID-19 pandemic

B. Collins1, C. Bom Kahama2, D. Raben2

13:50-14:15

 

Discussion

 

14:15-14:30

 

Break

Break
Break

14:15-14:30

 

Break

ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage
14:30 - 15:30
Abstract driven session

14:30-15:30

AS1

ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage

Session objectives: To share innovative programmes and experiences for implementing new testing and sampling technologies to increase HIV, viral hepatitis, STI and TB testing coverage based on submitted conference abstracts.

Moderators:

Cary James, World Hepatitis Alliance

Valerie Delpech, Public Health England

14:30-14:37

AS1/01

RiskRadar: the 1st integrated ICT tool on combination prevention for hepatitis/HIV/TB/STI

L. Cosmaro1, D. Savarino1, M. Mommi2, Z. Dominkovic3, A. Simkunaite-Zazecke4, L. Stoniene5, A. Raahauge6, C. Kakalou7, V. Drosou8, P. Natsiavas7

14:37-14:44

AS1/02

An evaluation of the outcomes of an online HIV self-sampling service to inform risk communication and future online testing policy

J. Taylor1,2, G. Holdsworth1, S. Amos-Gibbs1, E. Ardines1, B. George1, J. Harbottle1, P. Baraitser1,3

14:44-14:51

AS1/03

Efficacy of an on-screen computer reminder for HIV screening in primary care based on indicator conditions: a cluster randomized controlled trial

C. Agustí1,2, O. Cunillera3, J. Almeda3, J. Mascort4,5, R. Carrillo4,5, C. Olmos3, J. Casabona1,2

14:51-14:58

AS1/04

Breaking the Chain? A once in a generation opportunity to find and treat HIV during UK’s COVID-19 lockdown

A. Basu1, B. George1, G. Holdsworth1

14:58-15:30

 

Discussion

E-poster sessions (live Q&A)/break
15:30 - 16:30
E-Poster sessions

Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned

PO1/01

Impact of the COVID-19 pandemic on community-based testing for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region

L. Fernàndez-López1,2,
D. Simões3,4, M. Krone5,

J. Casabona1,2

PO1/02

Screening, diagnosis and treatment of HCV/HIV during the COVID 19 pandemic: lessons from a Mobile Outreach Program in Lisbon, Portugal

F. Barata1, C. Pereira1, I. Pereira1,

H. Faria1, R. Sousa Coutinho1, D. Gil Morais1

PO1/03

Impact of COVID-19 on a Portuguese ONG screening site: implications for practice

A.L. Rosa1, P. Morais1, E. Sávio1,

J. Conceição1, C. Rodrigues1

PO1/04

Strengthening community responses on prevention and care for PLHIV and key populations during the COVID-19 emergency crisis

M. Reiriz Rojas1, A. Bertó Moran1,

D. García Morcillo1

PO1/05

Going cashless in a cash-constrained crisis: Implementation of a COVID-19 emergency response program for optimising engagement in HIV care among Thai men who have sex with men and transgender women

T. Anand1, C. Nitpolprasert1

PO1/06

Use of mobile applications and social networks for HIV testing among MSM and PrEP obtaining at COVID-19 conditions, in Ukraine

A. Chernyshev1, A. Bogoslavets1,

R. Marchenko1

 

Poster Session 2 (PO2): Impact of COVID-19 on provision of services for people who inject/use drugs

PO2/01

Changes to the provision of services for people who inject drugs in England, Wales and Northern Ireland during the COVID-19 pandemic

S. Croxford1, E. Emanuel1,

A. Ibitoye1, J. Njoroge1, C. Edmundson1, L. Slater1, E. Phipps1

PO2/02

COVID-19 impact on harm reduction programs (testing and counselling) in low threshold drug services in Germany

A. Krings1, G. Steffen1, C. Germershausen1, R. Zimmermann1

PO2/03

The impact of the COVID-19 pandemic on harm reduction services in a prison and addiction centres in the Balearic Islands, Spain: preliminary results from a novel hepatitis C elimination programme

A. Herranz1, À. Vilella2, A. Agius3,

J.M. Alonso4, A. Rodríguez5,

C.A Picchio1, D. Guy1, C. Pujol1, M. Buti6,7, J. Lazarus1

PO2/04

Using peer support to facilitate hepatitis C treatment during the COVID-19 pandemic

J.S. Lambert1,2, B. West2,

T. McHugh1, J. Farrell2, C. Moran2,

l. Vidal1

Poster Session 3 (PO3): New testing technologies to increase testing coverage: HIV self-testing and home-based sampling

PO3/01

Key learnings from an HIV at-home testing campaign for Dutch MSM and trans people during the COVID-19 pandemic

K. Vermey1, P. Zantkuijl1, H. Bos1,

M. Lasschuyt2, K. Visser2, W. Zuilhof1

PO3/02

Self HIV testing in Poland implementation during COVID-19

M. Ankiersztejn-Bartczak1,

A. Stola1,2

PO3/03

Preliminary results of a pilot project on HIV self-testing among men who have sex with men in the City of Zagreb, Croatia, 2020/2021

N. Bogdanić1, D. Dubravić2,

J. Kresović2, M. Erceg2, A. Dišković2, T. Beganović2, Š. Zekan1, J. Begovac1

PO3/04

Get an HIV test at home! Increasing access to testing, in the pandemic context, by implementing a pilot program of home-based HIV testing in Romania

M. Lixandru1, S. Ciobanu1,

C.-L. Hanu1, A. Schiau1

PO3/05

TESTATE C Plus: an online self-sampling intervention for hepatitis C in gay, bisexual and other men who have sex with men and trans women in Catalonia (Spain)

C. Agustí1,2, H. Martínez1,

E. Martró3,2, S. Moreno1, E. Muntada1,

P. Romano1, L. Egea1, R. Mora4,

L. Villegas4, J. Mena4, Q. Roqueta5,

J. Hernández6, M. Vázquez6, A. Not3, A. Pérez3, J. Colom7, J. Casabona1,2

PO3/06

High acceptability and effectiveness of an online self-sampling intervention for HIV in gay, bisexual and other men who have sex with men and trans women in Spain (TESTATE VIH)

C. Agustí Benito1,2, H. Martínez1,

V. González1, S. Moreno1,

E. Muntada1, P. Romano1, L. Egea1, R. Muñoz1, J. Hoyos3,2, J. Casabona1,2

 

 

PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC)
16:30 - 17:45
Plenary Session
Abstract Driven Session

16:30- 17:45

PS4

PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC)

Moderators:

Anne Bergenström, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

Viktor Mravčík, Head of the National Monitoring Centre for Drugs and Addictions, Czechia

16:30-16:40

PS4/01

Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: European perspectives

Thomas Seyler, EMCDDA

16:40-16:50

PS4/02

New evidence on testing and linkage to care for PWIDs

Otilia Mardh, European Centre for Disease Prevention and Control (ECDC)

16:50-17:00

PS4/03

Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemic

Marios Atzemis, Positive Voice, Greece

17:00-17:10

PS4/04

What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs?

Fadi Meroueh, Montpellier University Hospital, France

17:10-17:45                

 

Panel Discussion

Moderator: Linda Montanari, EMCDDA

PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB
16:30 - 17:45
Plenary Session
Abstract Driven Session

16:30-17:45

PS2

PLENARY SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB

Session objectives: To share advances in prevention programming; define the concept of combination prevention in HIV, hepatitis, STIs and TB, highlighting good examples of how combination prevention can be implemented as a strategy and enlarged as a people-centered approach.

Moderators:

Ben Collins, ReShape/International HIV Partnerships

Teymur Noori, European Centre for Disease Prevention and Control (ECDC)

16:30-16:40

PS2/01

“Prevention is hard, Combination is key” – Good example of HIV/STI combination prevention in Scotland

Claudia Estcourt, Glasgow Caledonian University, Scotland, United Kingdom

16:40-16:50

PS2/02

Combination disease prevention in prisons: a comprehensive programme in Luxembourg

Patrick Hoffmann, Luxembourg Directorate of Health

16:50-17:00

PS2/03

TB an HBV/HCV/HIV-combined preventive activities in the Netherlands

Gerard de Vries, RIVM, Netherlands

17:00-17:10

PS2/04

The ‘Get Tested LeEDs’ project: clinical impact and cost-effectiveness of opt-out emergency department testing for bloodborne viruses (BBVs) in England

E. Smout1, J. Williams2, A. Miners2, K. Phyu3, L Parker3, A Evans3, J McLaren3, M. Aldersley3, G. Hughes1, M. Ruf4, E. Page3

17:10-17:45

 

Discussion

 

Break
Break

17:45-18:00

 

Break

EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action
18:00 - 19:30
EU Health Project Symposium

18:00-19:30

 

EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action

Session objectives: To discuss integration of infectious diseases and ways to ensure sustainability and improvement of integrated health care models.

Moderators:

Luis Mendão, GAT Portugal

Dorthe Raben, CHIP/INTEGRATE Coordinator

18:00-18:05

 

The INTEGRATE Story & INTEGRATE at HepHIV

Dorthe Raben, CHIP/INTEGRATE Coordinator

18:05-18:30

 

Video presentation of the processes behind the main outcomes of the INTEGRATE JA

Short intro to the Online training module on prevention, testing and linkage to care

 

18:30-19:30

 

Panel discussion: Integration of Infectious Diseases – keeping the momentum

Valerie Delpech, Public Health England, UK

Lella Cosmaro, Lila Milano, Italy

Jordi Casabona, El Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Catalonia, Spain

Ann Sullivan, SSAT Chelsea Westminister Hospital, UK

Nadia Gasbarrini, Villa Maraini, Italy

Jack Lambert, University of Dublin & Mater Misericordiae University Hospital, Ireland

Walter Cullen, University of Dublin, Ireland

Jeff Lazarus, Barcelona Institute for Global Health (IS Global), Catalonia, Spain

Teymur Noori, European Centre for Disease Prevention and Control (ECDC)

Thomas Seyler, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

Ana Gutierrez Burgos, European Commission, DG SANTE

 

 

Friday, 7 May 2021
Friday, 7 May 2021
PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: COVID-19’s impact on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building stronger systems and communities in light of lessons learned
13:00 - 14:15
Plenary Session

13:00-14:15

PS3

PLENARY SESSION 3: Implementing integrated testing strategies

Session objectives: To present examples of innovative integrated testing programmes for HIV, viral hepatitis, STIs and/or TB and highlight effective implementation models of integrated testing and linkage to care at different service levels.

Moderators:

Jordi Casabona, El Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT) Catalonia, Spain

Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)

 

 

Short report from Day 1 deleted

 

13:00-13:10

PS3/01

Experience in innovative approach to testing for HIV, hepatitis and STIs

Raimonda Matulionytė, Vilnius University Hospital Santaros Klinikos, Lithuania

13:10-13:20

PS3/02

Integrated screening for TB, HIV and HCV at the primary healthcare level

Maka Danelia, National Center for Disease Control and Public Health, Georgia

13:20-13:30

PS3/04

Evolution of key indicators for community-based voluntary counseling and testing activity in Europe: COBATEST Network 2017-2019

M. Gogishvili1, L. Fernàndez López1,2,3, J. Casabona Barbarà1,2,3

13:30-13:40

PS3/05

Implementing self-test programmes during COVID-19

Robert Hejzak, Czech AIDS Help Society

13:40-14:15

 

Discussion

Break
Break

14:15-14:30

 

Break

ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD
14:30 - 15:30
Abstract driven session

14:30-15:30

AS2

ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD

Session objectives: To share and discuss experiences in implementing testing and care models for people who inject or use drugs and provide European and global overviews of harm reduction and care responses (for people who inject or use drugs), including responses to the global COVID-19 pandemic.

Moderators:

Eberhard Schatz, Correlation Network

Lella Cosmaro, Lila Milano, Italy

14:30-14:37

AS2/01

Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the implementation of a three level HCV elimination strategy

S. Ciobanu1, A. Bocai1, M. Dan1, A. Luca1, R. Teodorescu1

14:37-14:44

AS2/02

Integrated harm reduction responses to HIV and viral hepatitis in the COVID-19 pandemic: a global overview

S. Shirley-Beavan1, R. Csak1, C. Daniels1, N. Burke-Shyne1, G. Lasco2, M. Platko3, J. di Iorio4, C. Ahumada4, S. Hajal5, E. Aaraj5, C. Baguma6, K. Naik7

14:44-14:51

AS2/03

Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, Italy

S. Mazzilli1,2, T. Sebastiani3, V. Casigliani1, G. Cocca3, A. Stemat3, C. Nicola3, C. Selva3, C. Catani3, L. Tavoschi1, R. Ranieri3

14:51-14:58

AS2/04

Blood-borne virus testing in people who inject drugs with a history of sex work

E. Emanuel1, S. Croxford1, E. Phipps1, A. Ibitoye1, J. Njoroge1, C. Edmundson1, L. Slater1

14:58-15:05

AS2/05

HCV care for PWID in Europe - results from a civil society-led monitoring

R. Rigoni1, T. Tammi2, E. Schatz1

15:05-15:30

 

Discussion                                                                                                                        

 

 

E-poster sessions (live Q&A)/Break
15:30 - 16:30
E-Poster sessions

Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings

PO4/01

Socio-demographic inequalities in HIV testing patterns among MSM in Spain

C. Folch1, A. Díaz2, M.C. Vázquez3,

S. Meyer4, J. Casabona1

PO4/02

Towards a hepatitis C-free hospital: results after one year of hepatitis C virus screening in a tertiary hospital emergency department in a high-income country

J. Llaneras Artigues1, A. Barreira-Díaz1, A. Rando Segura1, J. Bañares Sanchez1, B. Meza Ramos1, L. Ruíz Ortega1, J.R. Marques Soares1,

A. Monforte Pallares1, O. Orozco Gálvez1, M. Riveiro-Barciela1,

F. Velasquez Orozco1, F. Rodríguez-Frías1, M. Arranz Betegon1, R. Esteban Mur1, M. Buti Ferret1

PO4/03

Implementation of HIV rapid testing model in government medical facilities in Leningrad Region, Russia in 2020

S. Semikova1, P. Supronenko2,

V. Stanilevskiy2, M. Petrova3,

O. Prokof’eva4, V. Surkova5,

A. Merzlyakova6, Y. Godunova6,

A. Kovelenov1, A. Chuykov2, N. Mironova2, A. Zakowicz7

PO4/04

Quality of life in people living with HIV in Romania and Spain

J. Lazarus2, M. Kall1, U. Fresán2,3,

D. Guy2, G. Brown4, C. Burgui5,

J. Castilla5, V. Ionel Grecu6,

F. Dumitrescu6, V. Delpech1

PO4/05

HCV screening of immigrants at arrival: an opportunity to linkage to care of a population with limited access to Health Care system

M. Riveiro-Barciela1,2, B. Treviño3,

N. Serre3, A. Rando4, F. Salvador3,

A. Barreira-Díaz1, A. Palom1,

E. Vargas1, D. Pou3, L. Roade1,2,

I. Molina3, F. Rodríguez-Frías2,4,

M. Buti1,2

PO4/06

Expanding integrated HCV/HIV testing to alcohol dependent clients attending treatment centres for drug and alcohol dependency in Lithuania

L. Stoniene1, E Subata1,

A Sirvinskiene1, A Grice1,

M.L. Jakobsen2, S. Finne Jakobsen2,

D. Raben2, C. Rae3, A. Sullivan3

PO4/07

Distributing a questionnaire for women attending a Sexual Health Clinic increases PrEP uptake

S. Strachan1,2, S. Jaffer1, V. Apea3,

D. Campbell4, J. Domino5, L. Davies1,

J. Dugdale6, K. Nambier7, D. Onyago8, J. Otti2, M. Ross9, J. Stevenson2,

N. Turner1, G. Singh1, A. Sullivan1

PO4/08

HIV and viral hepatitis transmission knowledge among female health care providers and females in the general population in Constanta Region, Romania

A.-M. Schweitzer1, M. Bogdan1,

F.S. Stoian1, I. Ciocea1

Poster Session 5 (PO5): Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings

PO5/01

Community-based voluntary counseling and testing for HIV, sífilis and HCV in Europe: COBATEST Network 2019

M. Gogishvili1, L. Fernàndez López1,2,3, J. Casabona Barbara1,2,3

PO5/02

Rapid Hiv test in Sardinia, a lookback at first 5 years of Lila Cagliari testing service

G. Dessì1, F. Cardinale1, V. Mascia1

 

PO5/03

Reaching 95-95-95: 3 years of the Portuguese League Against AIDS performing screening tests and promoting therapeutical compliance

M.E. Saraiva1, S. Melo Refoios1,2,

M. Ferrão1, G. Bento3, R. Castro4,

R. Vicente5, L. Nunes5

PO5/04

Promoting autonomy and self-care of people living with HIV and/or hepatitis through a community-based approach: the example of the Takari project in French Guiana

A.-S. Petit1,2, J.-P. Dada3, L. Napuchi3, C. Mathurin4, M. Shahisavandi4,

M. Préau1, D. Michels2,5, M. Gaillet6,

C. Michaud6, C. Piedrafita y Costa3

PO5/05

Contributions of (+) Screening = (+) Life Project in the access of the Trans and Sex Worker population to early detection and screening of STIs

P. Costa1, F. Aguiar1, S. Correia1,

A. Silva2, P. Belmonte1, F. Neves3

Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs

PO6/01

Point-of-care screening combined with nursing and peer-based outreach work to enhance testing and treatment for hepatitis C among people who use drugs, people who experience homelessness, and migrants: the REACH U Study 

C. Merendeiro1, R. Lopes1, I. Marinho1, R. Marinho2, J. Grebely3, A. Nave1

PO6/02

Efficiency of HIV rapid testing and social services for IDU women in Tomsk, Russia

E. Borzunova1, A. Chernov2,

V. Stanilevskiy3, N. Mironova3,

A. Chuykov4, A.M. Żakowicz4

PO6/03

Hepatitis C cascade of care (CoC) for people who use drugs (PWUD) under opiate substitution treatment (OST) in Greece

O. Anagnostou1, K. Micha1, K. Kaliva1, E. Tsirogianni1, E. Petroulaki1, I. Detsi1, M. Kollitsida1, G. Androulakis1,

M. Gargoulaki1, V. Karagounis1,

A. Katsili1, S. Kollia1, A. Kotsalis1,

M. Spirellis1, K. Stamatopoulos1,

V. Stavridou1, C. Tanis1, P. Tsekoura1, Y. Topalidou Stepin1, A. Tsantilas1,

M. Chalkiadakis1, A. Drimousi1,

N. Papadopoulos2, A. Theocharis1

PO6/04

Decentralized HCV consultation: an HCV micro-elimination project in the community

Á. Ávila1, T. Azevedo1, M.J. Braz1,

S. Busi1, F. Calinas2, R. Costa1,

T. Mamede1, C. Marques1, R. Pires1,

J. Santa Maria1

PO6/05

Portugal’s first mobile drug consumption room: client characteristics and linkage to care

H. Taylor1, A. Curado1, Â. Leite1,

J. Pires2, V. Correia1, P. Nunes2,

J. Caldas1, M. Alves2, J. Canêdo1,

D. Gautier2

PO6/06

Could the 2010 HIV outbreak in Athens, Greece be prevented? A mathematical modelling study

I. Gountas1, G. Nikolopoulos2,

G. Touloumi3, A. Fotiou4, K. Souliotis1

PO6/07

Eliminating hepatitis C on the Balearic Islands by linking patients who use drugs from addiction service centers, a local NGO, a prison and a mobile methadone bus to HCV care

J.V Lazarus1, À. Vilella2, C.A Picchio1, A. Herranz1, M. Buti3,4

PO6/08

Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs (PWUD)

J. Valencia1, P. Ryan1, J. Lazarus2,

J. Troya1, G. Cuevas1, I. Cañamares1,

I. Escobar1

PO6/09

Designing a strategy to reengage PWID lost to follow-up in HIV care, the case of the PISCIS Cohort in Spain

J. Palacio-Vieira1,2, J.M. Reyes-Urueña1,2,3, A. Imaz4, A. Bruguera1,3,

L. Force5, A.-J. Orti-Llaveria6,

J.-M Llibre7, I. Vilaró8, F. Homar Borràs9, V. Falcó10,11, M. Riera12,

P. Domingo13, E. de Lazzari14,

I. Chivite14, E. Letang15, J.-M Miró14,

J. Casabona1,2,3,16

PO6/10

Impact of opiate substitution treatment (OST) on hepatitis and HIV high risk behaviors

M. Vasileiou1, O. Anagnostou2, I. Elefsiniotis3

 

 

 

 

 

 

PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC)
16:30 - 17:45
Plenary Session
Abstract Driven Session

16:30- 17:45

PS4

PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC)

Session objectives: To provide an overview of the latest evidence on prevention, testing and linkage to care for people who use or inject drugs, highlighting the importance of prison settings for increasing diagnosis and care for people who inject drugs, and to discuss the impact of COVID-19 on the provision of services for people who use drugs.

Moderators:

Anne Bergenström, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

Viktor Mravčík, Head of the National Monitoring Centre for Drugs and Addictions, Czechia

16:30-16:40

PS4/01

Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: European perspectives

Thomas Seyler, EMCDDA

16:40-16:50

PS4/02

New evidence on testing and linkage to care for PWIDs

Otilia Mardh, European Centre for Disease Prevention and Control (ECDC)

16:50-17:00

PS4/03

Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemic

Marios Atzemis, Positive Voice, Greece

17:00-17:10

PS4/04

What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs?

Fadi Meroueh, Montpellier University Hospital, France

17:10-17:45                

 

Panel Discussion

Moderator: Linda Montanari, EMCDDA

17:45-18:00

 

Break

Break
Break

17:45-18:00

 

Break

CLOSING SESSION: Integrating disease areas and settings
18:00 - 19:15
Closing Session


18:00-19:15

 

CLOSING SESSION: Integrating disease areas and settings

Session objectives: To discuss lessons learned and next steps for integration of service delivery in infectious diseases; to present and discuss the Conference Call to Action and implications for policy and implementation agendas.

Moderator:

Michel Kazatchkine, Special Advisor to the Joint United Nations Program on AIDS (UNAIDS) for Eastern Europe and Central Asia

18:00-18:15

 

Short report from Conference Days 1 and 2 and Best Poster Award

Jürgen Rockstroh, HepHIV2021 Conference Co-chair, HIV Outpatient Clinic, University of Bonn, Germany

18:15-19:05

 

Panel Discussion: Integrated testing and linkage to care for HIV, viral hepatitis, TB, STIs and other infectious diseases: Paving the way forward amidst a global pandemic

Panellists:

Cary James, World Hepatitis Alliance

Andrew Winter, IUSTI Europe

Jens Lundgren, CHIP, University of Copenhagen

Nicole Seguy, WHO Regional Office for Europe

Yazdan Yazdanpanah, ANRS Maladies Infectieuses Emergentes, France

Nikoloz Chkhartishvili, Infectious Diseases, AIDS & Clinical Immunology Research Center (IDACIRC), Georgia
Paul Sommerfeld, TB Europe Coalition

Nikos Dedes, European AIDS Treatment Group (EATG)

Ricardo Baptista Leite, MP Portugal, UNITE

HepHIV 5 - 7 May 2021 (Time CEST) / Lisbon & Virtual
Wednesday, 5 May 2021
  • EATG stakeholder meeting regarding diagnostics
    09:30 - 11:00
  • Lisbon Fast Track City: HCV testing and treatment in the community – learning from harm reduction and people who use drugs
    11:30 - 13:00
  • Fast-Track Cities: Actioning HCV Elimination in European Urban Settings
    13:30 - 14:30
  • OPENING SESSION
    15:00 - 17:00
Thursday, 6 May 2021
  • COBATEST network executive meeting (Closed meeting))
    10:00 - 13:00
  • PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: COVID-19’s impact on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building stronger systems and communities in light of lessons learned
    13:00 - 14:15
  • Break
    14:15 - 14:30
  • ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage
    14:30 - 15:30
  • E-poster sessions (live Q&A)/break
    15:30 - 16:30
  • PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC)
    16:30 - 17:45
  • PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB
    16:30 - 17:45
  • Break
    17:45 - 18:00
  • EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action
    18:00 - 19:30
Friday, 7 May 2021
  • PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: COVID-19’s impact on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building stronger systems and communities in light of lessons learned
    13:00 - 14:15
  • Break
    14:15 - 14:30
  • ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD
    14:30 - 15:30
  • E-poster sessions (live Q&A)/Break
    15:30 - 16:30
  • PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC)
    16:30 - 17:45
  • Break
    17:45 - 18:00
  • CLOSING SESSION: Integrating disease areas and settings
    18:00 - 19:15
Go to Top
UMSA Library
N.TitleAction
1Document Sample

Click to Open

2Document Sample

Click to Open

3Document Sample

Click to Open

4Video Sample

Click to Open

5Video Sample

Click to Open

6Video Sample

Click to Open

1:1 meeting scheduling

Videos on Demand
Session NumberPresenterSessionPresentation titleAccess
OS-1Daniel Simões (mod.), Jürgen Rockstroh (mod.) Ricardo Baptista Leite, Dorthe RabenOpening Session Part 1 of the live transmission (OS)View Session
OS-2António Lacerda SalesOpening Session Welcome message from the Portuguese Minister of HealthView Session
OS-3John RyanOpening Session Welcome from the European Commission: The EU response on HIV, viral hepatitis, STIs and TB in the futureView Session
OS-4Andrea AmmonOpening Session Post-2020/Covid-19 and progress towards the SDG targets: Where are we ?View Session
OS-5Hans KlugeOpening Session ‘The changed landscape’ – providing testing for HIV/STIs/hepatitis/TB in the era of COVID-19View Session
OS-6Daniel Simões (mod.), Jürgen Rockstroh (mod.), Rui Portugal; Panel discussion feat. all speakers of the OSOpening Session Part 2 of the live transmission (OS)View Session
PS1-1C. LanePlenary Session 1Perspectives from the US National Institute of Allergy and Infectious Diseases of the National Institutes of HealthView Session
PS1-2A. SullivanPlenary Session 1Impact of the COVID-19 pandemic on linkage to and retention in care for HIV, hepatitis B and C and sexually transmitted infections in the WHO European RegionView Session
PS1-3C. KantwerkPlenary Session 1s.a.m Health: Germany’s first digital sexual health service is providing COVID-safe remote STI testing and counselling during the Covid-19 Pandemic and beyondView Session
PS1-4V. StanilevskiyPlenary Session 1Rapid HIV testing and linkage in rehabilitation centers during COVID-19 pandemics, Yekaterinburg and Sverdlovsk region, RussiaView Session
PS1-5B. CollinsPlenary Session 1European testing week: adaptation of testing services during the COVID-19 pandemicView Session
AS1-1L. CosmaroAbstract Driven Session 1RiskRadar: the 1st integrated ICT tool on combination prevention for hepatitis/HIV/TB/STIView Session
AS1-2J. TaylorAbstract Driven Session 1An evaluation of the outcomes of an online HIV self-sampling service to inform risk communication and future online testing policyView Session
AS1-3C. AgustíAbstract Driven Session 1Efficacy of an on-screen computer reminder for HIV screening in primary care based on indicator conditions: a cluster randomized controlled trialView Session
AS1-4A. BasuAbstract Driven Session 1Breaking the Chain? A once in a generation opportunity to find and treat HIV during UK’s COVID-19 lockdownView Session
PS2-1C. EstcourtPlenary Session 2“Prevention is hard, Combination is key” – Good example of HIV/STI combination prevention in ScotlandView Session
PS2-2P. HoffmannPlenary Session 2Combination disease prevention in prisons: a comprehensive programme in LuxembourgView Session
PS2-3G. de VriesPlenary Session 2Good example of TB combination prevention in NetherlandsView Session
PS2-4E. SmoutPlenary Session 2The ‘Get Tested LeEDs’ project: clinical impact and cost-effectiveness of opt-out emergency department testing for bloodborne viruses (BBVs) in EnglandView Session
PS3-1Raimonda MatulionytėPlenary Session 3Experiences in innovative testing approaches for HIV, hepatitis, STIs and TBView Session
CSMichel Kazatchkine (Moderator) Jürgen Rockstroh (Moderator), Cary James, Andrew Winter, Jens Lundgren, Nicole Seguy, Yazdan Yazdanpanah, Nikoloz Chkhartishvili, Paul Sommerfeld, Nikos Dedes, Ricardo Baptista LClosing SessionIntegrating disease areas and settingsView Session
PS3-2Maka DaneliaPlenary Session 3Integrated screening for TB, HIV and HCV at the primary healthcare levelView Session
PS3-3M. GogishviliPlenary Session 3Evolution of key indicators for community-based voluntary counseling and testing activity in Europe: COBATEST Network 2017-2019View Session
PS3-4Robert HejzakPlenary Session 3Implementing self-test programmes during COVID-19View Session
AS2-1R. TeodorescuAbstract Driven Session 2Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the implementation of a three level HCV elimination strategyView Session
AS2-2S. Shirley-BeavanAbstract Driven Session 2Integrated harm reduction responses to HIV and viral hepatitis in the COVID-19 pandemic: a global overviewView Session
AS2-3S. MazzilliAbstract Driven Session 2Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, ItalyView Session
AS2-4E. EmanuelAbstract Driven Session 2Blood-borne virus testing in people who inject drugs with a history of sex workView Session
AS2-5R. RigoniAbstract Driven Session 2HCV care for PWID in Europe - results from a civil society-led monitoringView Session
PS4-1Thomas SeylerPlenary Session 4Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: a European perspectiveView Session
PS4-2Otilia MardhPlenary Session 4New evidence on testing and linkage to care for PWIDsView Session
PS4-3Marios AtzemisPlenary Session 4Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemicView Session
PS4-4Fadi MerouehPlenary Session 4What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs?View Session
Eposter Library
Programme Day 2
View Fullscreen
Programme Day 1
View Fullscreen
Channel 1
Rate

Please give a rate

Comments to author

    Your Name (required)


    Your Email (required)




    Your subject


    Your comments to author


    Rating

    Please give a rate



    Dr. Begoña Bermejo

     

    Physician and medical doctor from the University of Cadiz. Medical oncologist at the Clinical University Hospital of Valencia and Biomedical Research institute INCLIVA
    Associate Professor of Medicine School at University of Valencia

    She develops her assistance and research work in the breast pathology unit. She has an extensive experience in clinical trials and research projects in the area of breast cancer.Member of the breast cancer research group at the Carlos III institute.Member of the board of GEICAM (Spanish Breast Cancer Research Group)

     

    Dr. Enrique Santas Olmeda

     

    Dr. Enrique Santas, MD, PhD,  is a cardiologist at the Hospital Clínico Universitario in Valencia (Spain). He is an active clinician and an emergent researcher, with a focus on heart failure and cardiac imaging. Currently, he is the director of the cardio-oncology program at his institution, dedicated to the cardiovascular health of patients undergoing cancer treatment as well as cancer survivors.

     

    Join a meeting